Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
You are here: Home / Top Stories / : Amgen’s cancer-drug pipeline looks promising despite FDA setback, analysts say
Market News and Views
Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade